Exane Derivatives’s Sarepta Therapeutics SRPT Stock Holding History

Exane Derivatives’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$225	Sell	3 -43	-93%	-$3.16K	﹤0.01%	662
2022 Q1	$3.59K	Sell	46 -12	-21%	-$919	﹤0.01%	715
2021 Q4	$5.22K	Sell	58 -392	-87%	-$33.5K	﹤0.01%	616
2021 Q3	$41.6K	Sell	450 -95	-17%	-$7.32K	0.01%	637
2021 Q2	$37.8K	Hold	545	–	–	0.01%	664
2021 Q1	$40.6K	Sell	545 -91	-14%	-$8.4K	0.01%	535
2020 Q4	$108K	Hold	636	–	–	0.03%	386
2020 Q3	$89.3K	Hold	636	–	–	0.03%	310
2020 Q2	$102K	Hold	636	–	–	0.03%	291
2020 Q1	$62.2K	Sell	636 -1,387	-69%	-$159K	0.02%	339
2019 Q4	$263K	Hold	2,023	–	–	0.05%	224
2019 Q3	$152K	Hold	2,023	–	–	0.03%	275
2019 Q2	$307K	Hold	2,023	–	–	0.05%	216
2019 Q1	$241K	Buy	2,023 +285	+16%	+$36.6K	0.05%	203
2018 Q4	$190K	Buy	1,738 +338	+24%	+$42.3K	0.03%	253
2018 Q3	$226K	Hold	1,400	–	–	0.04%	233
2018 Q2	$185K	Buy	+1,400	New	+$132K	0.03%	272

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Exane Derivatives's SRPT Position: Q2 2022 in Review

Exane Derivatives reduced its Sarepta Therapeutics (SRPT) stake by 93% in Q2 2022, selling an estimated $3.16K and leaving 3 shares worth $225. The position accounts for ﹤0.01% of the portfolio, ranked #662.

Exane Derivatives first reported a position in SRPT in Q2 2018 and has held it in 17 quarters since. The position peaked at $307K in Q2 2019. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

Exane Derivatives held 3 shares of Sarepta Therapeutics worth $225 as of Q2 2022.
Exane Derivatives sold 43 Sarepta Therapeutics shares in Q2 2022, an estimated $3.16K.
Sarepta Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #662 holding.
Exane Derivatives first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 17 quarters since.
Exane Derivatives's Sarepta Therapeutics position peaked at $307K in Q2 2019.
332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.